Unichem Laboratories Ltd.
Snapshot View

296.10 -10.25 ▼-3.4%

05 August 2021, 04:00:00 P.M.
Volume: 10,942

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.unichemlabs.com
Financial Indicators
Market Cap 2,084.71 Cr.
Earnings per share (EPS) 2.90 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 102.19 Trailing Twelve Months Ending 2021-06
Industry PE 32.74 Trailing Twelve Months Ending 2021-06
Book Value / Share 360.44 Trailing Twelve Months Ending 2021-06
Price to Book Value 0.82 Calculated using Price: 296.10
Dividend Yield 1.36 Period Ending 2021-03
No. of Shares Subscribed 7.04 Cr. 70,405,751 Shares
FaceValue 2
Company Profile

Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.

The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.

Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa, Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh) and Baddi (Himachal Pradesh).

The company’s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The manufacturing plants have also received ISO 9001:2000 and ISO 14001:2004 certifications for quality management.

Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.

Milestones

1944- Unichem was commissioned by Late Amrut Mody.

1952- The company forayed into exporting activities.

1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.

1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.

1963- The company entered co-marketing of formulations tie up with Uni Sankyo.

1968- Unichem set up a formulation plant at Ghaziabad.

1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.

1972- As an acknowledgement for Late Amrut Mody’s  pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.

1973- Unichem's research laboratory was recognised for Phd work by Bombay University. Unichem's R&D centre was recognised by Department of Science and Technology.

1976- The company set up a fine chemicals unit at Roha.

1978- Unichem commissioned its Roha bulk drug plant.

1979- The company received its first clearance from drug authorities for NEFEDIFINE.

1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in India.

1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).

1987- The company entered the animal health care business.

1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.

1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.

1997- The company’s formulation plant located at Goa was commissioned. It set up new corporate office set up at Unichem Bhavan Jogeshwari, Mumbai.

1998- The company’s formulations plant located at Baddi was fully operational.

1997-2000- The company implemented BaaN ERP.

1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.

2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for Goa and Baddi Plants

2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at Bangalore that would conduct research work in Bio-technology

2002- It formed a joint venture in UK called Niche Generics.

2002-2003- The company divested its animal healthcare division. It established subsidiaries in South Africa and Brazil. The company also undertook modernization of formulations plant located at Ghaziabad.

2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.

2005- The company set up of new pharma technology development center located at Goa. Unichem Baddi Unit II plant was commissioned. It acquired API manufacturing unit at Pithampur

2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics, United Kingdom.

2007- Unikare division launched that catered to Dermatology and Allied therapies segment.

2013 - 14
• Commissioning of new R&D centre at Goa
• US FDA re-certification of Pithampur(API) Plant
• Acquired API Facility in Kolhapur, Maharashtra
2015 – 16
• Successful completion of US FDA Inspection at three plants
• Expansion of Goa Formulations Plant completed, increasing the capacities significantly
• Unienzyme launched for OTC market

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.35%
1 Week
-10.97%
1 Month
-9.28%
3 Month
-10.37%
6 Month
-7.31%
1 Year
+13.67%
2 Year
+74.38%
5 Year
+5.24%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 16.34 16.62 8.95 11.92 10.77 136.04 -0.90 -2.37 1.37
Return on Capital Employed (%) 20.13 21.84 9.29 14.97 13.42 162.77 -1.77 -1.49 2.12
Return on Assets (%) 11.00 11.56 6.55 8.82 7.68 108.06 -0.75 -1.94 1.11

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 727 817 868 954 1,064 2,680 2,620 2,531 2,557
Non Curr. Liab. 94 98 74 76 64 46 10 44 49
Curr. Liab. 251 230 212 275 393 464 503 567 506
Minority Int.
Equity & Liab. 1,073 1,145 1,153 1,305 1,521 3,190 3,133 3,142 3,112
Non Curr. Assets 594 564 589 673 772 854 1,094 1,455 1,734
Curr. Assets 478 581 564 632 748 2,336 2,039 1,686 1,377
Misc. Exp. not W/O
Total Assets 1,073 1,145 1,153 1,305 1,521 3,190 3,133 3,142 3,112

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 1,081 1,133 1,202 1,333 1,540 1,380 1,188 1,104 1,235
Other Income 17 42 21 19 6 3,278 98 91 50
Total Income 1,098 1,176 1,223 1,352 1,546 4,658 1,287 1,195 1,285
Total Expenditure -910 -956 -1,101 -1,169 -1,358 -1,358 -1,269 -1,155 -1,144
PBIDT 188 220 122 183 188 3,300 17 40 141
Interest -3 -3 -3 -3 -3 -8 -8 -8 -5
Depreciation -38 -46 -41 -39 -44 -51 -67 -82 -84
Taxation -33 -43 -2 -29 -33 -696 34 -12 -17
Exceptional Items -4
PAT 113 128 75 108 108 2,545 -24 -61 35

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 171 87 78 112 68 -112 -328 20 33
Cash Fr. Inv. -118 36 -52 -85 -128 1,648 -286 -36 -74
Cash Fr. Finan. -51 -95 -51 -33 59 -881 -2 -62 -121
Net Change 1 28 -25 -7 0 655 -616 -78 -162
Cash & Cash Eqvt 25 52 27 20 11 666 197 232 77

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 50.62 50.62 50.62 50.74 50.93 50.93 50.93 50.93 50.93
Public 49.38 49.38 49.38 49.26 49.07 49.07 49.07 49.07 49.07
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 02 Aug 2021
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
This is to inform you that the 58th Annual General Meeting (AGM) of the Company was held on Saturday July 31 2021 at 03:00 p.m. through video conference in terms of the circulars issued by MCA and SEBI.

Pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we submit herewith the following details of voting results through remote e-voting and voting at the Meeting which was conducted through video conference on each of the resolutions set out in the order.
Also find the Consolidated Scrutinizers Report dated July 31 2021 on remote e-voting and voting during the Meeting conducted through video conference. All the resolutions have been passed with requisite majority.
Mon, 02 Aug 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Unichem Laboratories Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here
Mon, 02 Aug 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations please find attached copies of the Financial Results for the quarter ended June 30 2021 published in newspapers on August 2 2021.

Technical Scans View Details

Wed, 04 Aug 2021
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,075.50 +0.2%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%